Verve Therapeutics (NASDAQ: VERV) is a biotechnology company created with a singular focus: to protect the world from heart disease. Verve is developing therapies to safely edit the genome of adults and confer lifelong protection from coronary artery disease, the most common form of heart disease and the leading cause of death worldwide. Verve was acquired by Eli Lilly in 2025.
Status: Acquired
Arvelle Therapeutics
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle Therapeutics was acquired by Angelini Pharma in January 2021.
RiskLens
RiskLens is the leading provider of quantitative cyber risk management software. Its platform is recognized as a mission-critical business application for cybersecurity and risk teams across the Fortune 1,000. RiskLens empowers large enterprises and government organizations to manage cyber risk from the business perspective by quantifying that risk in monetary terms. Clients depend on RiskLens solutions to better understand and communicate their cyber risk exposure in financial terms, prioritize their risk mitigations, measure the ROI of their security investments, and meet regulatory demands calling for the quantification of cyber risk. RiskLens is the only cyber risk quantification software purpose-built on FAIR, the standard quantification model for information security and operational risk. RiskLens was acquired by Safe Security in 2023.
Mineral Tree
Mineral Tree provides accounts payable automation software for finance professionals at growing organizations. Mineral Tree was acquired by Global Payments in 2021.
An Eight Roads investment. Eight Roads is F-Prime’s sister venture capital investment group, with which F-Prime collaborates on investments outside of the Americas and Europe.
* Denotes activity with the non-F-Prime investment team.
Securonix
Securonix is working to radically transform all areas of data security with actionable security intelligence. Their purpose-built, advanced security analytics technology mines, enriches, analyzes, scores and visualizes customer data into actionable intelligence on the highest risk threats from within and outside their environment. Using signature-less anomaly detection techniques that track users, account and system behavior, Securonix is able to detect the most advanced insider threats, data security and fraud attacks automatically and accurately.
An Eight Roads investment. Eight Roads is F-Prime’s sister venture capital investment group, with which F-Prime collaborates on investments outside of the Americas and Europe.
* Denotes activity with the non-F-Prime investment team.
Percy
Percy is a visual testing platform that automates the detection of UI changes by capturing screenshots, comparing them against baselines, and highlighting visual differences. Integrated into CI/CD workflows, Percy supports cross-browser and responsive testing, enabling teams to identify visual regressions early in the development process. Its AI-powered visual engine reduces false positives and streamlines the review process, facilitating faster and more confident releases.
Abelian Therapeutics
Nascent biotech company harnessing emerging science on the importance of Glia in brain disease. Abelian Therapeutics was acquired in September 2020.
BlackDuck
BlackDuck secures and manages open source software worldwide, eliminating open source security vulnerabilities & license compliance pain. BlackDuck was acquired by Synopsys in 2017.
A Fidelity Ventures investment. Fidelity Ventures was a venture capital investment group affiliated with F-Prime until 2010.
mindSHIFT
mindSHIFT is one of the largest IT outsourcing and cloud services providers. The company has supported our clients with tailored and trusted technology solutions for more than 15 years. From day-to-day IT to major systems modernization, count on mindSHIFT’s technology expertise and personalized customer care for all of your IT needs. mindSHIFT was acquired by Roche Company in 2014.
A Fidelity Ventures investment. Fidelity Ventures was a venture capital investment group affiliated with F-Prime until 2010.
Modis Therapeutics
Modis Therapeutics, Inc. was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company’s lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland CA, with offices in New York City. Modis was acquired by Zogenix.